# Patent

## Title
Triazine compounds and a process for preparation thereof

## Abstract

The present invention discloses triazine compounds of Formula II and a process to synthesize these compounds. Particularly, the invention provides one pot method to synthesize triazines nucleus, wherein the method comprises amination followed by using Leuckart reaction conditions of pyrrole/indole-2-carboxylates of Formula I to obtain corresponding triazine compounds of Formula II.

## Background
CROSS-REFERENCE TO RELATED APPLICATIONS
This application is a 35 USC §371 National Stage application of International Application No. PCT/IN2014/000056 filed Jan. 24, 2014, now pending; which claims the benefit under 35 USC §119(a) to India Application Serial No. 0197/DEL/2013 filed Jan. 24, 2013. The disclosure of the prior application is considered part of and is incorporated by reference in the disclosure of this application.
FIELD OF THE INVENTION
The present invention relates to triazine compounds and a process for preparation thereof. Particularly, the present invention relates to triazine compounds which are useful for screening of kinases and other related targets. More particularly, the present invention relates to the process for the preparation of novel triazine compounds.
BACKGROUND OF THE INVENTION
In the past decade, researcher's efforts focused at the discovery of therapeutically useful inhibitors of protein kinases have been intensified. These efforts have resulted in the identification of a variety of templates which, depending upon the nature of attached substituents, provide selective inhibition both within and across different protein kinase families. One such effort led to the discovery of pyrrolo[2,1-f][1,2,4]triazine nucleus as a novel kinase inhibitor template which effectively mimics the well-known quinazoline kinase inhibitor scaffold, which has been serving a core template for a variety of ATP-competitive kinase inhibitors.
Thus, the current trend of research is now focused on novel analogs of pyrrolo[2,1-f][1,2,4]triazine so as to provide potent biochemical inhibitors of the tyrosine kinase activity. There is ample literature available on synthesis of novel pyrrolo[2,1-f][1,2,4]triazine molecules.
Aqua mediated one pot facile synthesis of novel thioxo-1,2,4-triazin-5(2h)-one and [1,2,4]triazino[5,6-a]indole derivatives and their biological activities is disclosed by Harshita Sachdeva et al. in J. Chil. Chem. Soc, 57, No 4 (2012), págs: 1348-1354.
WO/2013/177983 (Yang Chunhao et al.) discloses pyrrolo[2,1-f][1,2,4]triazine compounds and their use for treating phosphatidylinositol-3 kinase related diseases such as cancer. EP2289894 (Dyckman Alaric et al.) relates to cycloalkyl, heterocyclo and heteroaryl pyrrolotriazine aniline compounds useful for treating p38 kinase-associated conditions.
Synthesis and antiproliferative activity of [1,2,4]triazino[4,3-a]indoles is reported in anticancer research 24: 3775-3780 (2004) by Paola Barraja et al.
An article titled “Discovery of pyrrolo[2,1-f][1,2,4]triazine C6-ketones as potent, orally active p38a MAP kinase inhibitors” by Dyckman A J, Li T, et al published in Bio. org Med ChemLett. 2011, Aug. 1; 21(15):4633-7 discloses preparation of Pyrrolo[2,1-f][1,2,4]triazine based inhibitors of p38a and explored functional group modifications at the C6 position and concludes that incorporation of aryl and heteroaryl ketones at this position led to potent inhibitors with efficacy in in vivo models of acute and chronic inflammation.
Another article titled “Synthesis and SAR of new pyrrolo[2,1-f][1,2,4]triazines as potent p38 alpha MAP kinase inhibitors” by Wrobleski S T et al published in Bio. Org. Med. Chem. Lett. 2008 Apr. 15; 18(8):2739-44, reports a novel series of compounds based on the pyrrolo[2,1-f][1,2,4]triazine ring system have been identified as potent p38 alpha MAP kinase inhibitors.
Yet another article titled “Synthesis of pyrrolo[2,1-f][1,2,4]triazine congeners of nucleic acid purines via the N-amination of 2-substituted pyrroles” by Shirish A. Patil et al published in J. O. Heterocyclic chemistry volume 31, issue 4, pages 781-786, describes synthesis of several new 4-mono- and 2,4-disubstituted pyrrolo[2,1-f][1,2,4]triazines. 1-aminopyrrole-2-carbonitrile intermediates were obtained by N-amination of the corresponding pyrrole-2-carboxaldehyde followed by CHO→CN conversion with either hydroxylamine-O-sulfonic acid or O-mesitylenesulfonylhydroxylamine. Cyclization of the product thus obtained with a variety of amidine reagents or, after conversion of the product to its corresponding amide followed by base-catalyzed annulation completed the synthesis of the title products.
OBJECTS OF THE INVENTION
The main objective of the present invention is to provide triazine compounds and a process for preparation thereof.
Another objective of the present invention is to provide a process for the preparation of novel triazine compounds.
Still another objective of the present invention is to provide triazine compounds which are useful for screening of kinases and other related targets.
SUMMARY OF THE INVENTION
Accordingly, the present invention provides triazine compounds of Formula II,




wherein, R1, R2, and R3, are independently selected from the group consisting of hydrogen, (C1-C6) alkyl, —NO2, I, Cl, Br, F, and —CH2—R7, where R7 is 5 or 6 membered saturated heterocyclic ring, comprising at least one heteroatom selected from the group consisting of N, O, and S which is directly attached to carbon atom of —CH2; or

R1 and R2 together form substituted or unsubstituted aromatic ring as set forth below:





wherein R4, R5, and R6 are individually selected from the group consisting of hydrogen, (C1-C6) alkyl, —NH2, halogen, —OH, —CN, —NO2, aryl, alkylaryl, (C1-C8) alkoxy, aryloxy, arylalkoxy, N3, and R—C≡C—, where R is selected from the group consisting of hydrogen, (C1-C6)alkyl, aryl, alkylaryl.

In one embodiment of the present invention the structural formula of the representative compounds of triazine compounds of Formula II are selected from the group consisting of:
















In another embodiment of the present invention triazine compounds of Formula II are useful for screening kinases and other related targets.
In an embodiment of the present invention a process for the preparation of triazine compounds of Formula II, said process comprising the steps of:

    
    
        (a) stirring compounds of Formula I with sodium hypochlorite, Methyl tertiary-butyl ether (MTBE), methyltrioctylammonium chloride (aliquat-336), aqueous NaOH, ammonium chloride and aqueous NH4OH at a temperature ranging between 25° C. to 35° C. for a period ranging between 2-4 hrs to obtain N-aminated substituted 2-carboxylate;
    
    






    
    
        
        
            wherein R1, R2, and R3, are independently selected from the group consisting of hydrogen, (C1-C6) alkyl, —NO2, I, Cl, Br, F, and —CH2—R7, where R7 is 5 or 6 membered saturated heterocyclic ring, comprising at least one heteroatom selected from the group consisting of N, O, and S which is directly attached to carbon atom of —CH2; or
            R1 and R2 together form substituted or unsubstituted aromatic ring as set forth below:
        
        
    
    






    
    
        
        
            wherein R4, R5, and R6 are individually selected from the group consisting of hydrogen, (C1-C6) alkyl, —NH2, halogen, —OH, —CN, —NO2, aryl, alkylaryl, (C1-C8) alkoxy, aryloxy, arylalkoxy, N3, and R—C═C, where R is selected from the group consisting of hydrogen, (C1-C6)alkyl, aryl, and alkylaryl
        
        
        (b) heating the N-aminated substituted 2-carboxylate compounds as obtained in step (a) with formamide and ammonium acetate at 130° C. to 140° C. for a period ranging between 10 to 12 hr under nitrogen atmosphere to obtain triazine compounds of Formula II.
    
    


In another embodiment of the present invention compounds of Formula I used in step (a) are selected from the group consisting of:

    ethyl 1H-pyrrole-2-carboxylate (5),
    ethyl 3,5-dimethyl-1H-pyrrole-2-carboxylate (6),
    ethyl 4-nitro-1H-pyrrole-2-carboxylate (7),
    ethyl 5-methyl-1H-pyrrole-2-carboxylate (8),
    ethyl 1H-indole-2-carboxylate (1),
    ethyl 5-methoxy-1H-indole-2-carboxylate (9),
    ethyl 5,6-dimethoxy-1H-indole-2-carboxylate (10),
    ethyl 5-(benzyloxy)-1H-indole-2-carboxylate (11),
    ethyl 5-cyano-1H-indole-2-carboxylate (12),
    ethyl 5-fluoro-1H-indole-2-carboxylate (13),
    ethyl 5-chloro-1H-indole-2-carboxylate (14),
    ethyl 5-bromo-1H-indole-2-carboxylate (15),
    ethyl 5-iodo-1H-indole-2-carboxylate (16),
    ethyl 5-hydroxy-1H-indole-2-carboxylate (17),
    ethyl 4-fluoro-1H-indole-2-carboxylate (18),
    ethyl 4-chloro-1H-indole-2-carboxylate (19),
    ethyl 4-bromo-1H-indole-2-carboxylate (20),
    ethyl 4-iodo-1H-indole-2-carboxylate (21),
    ethyl 4-hydroxy-1H-indole-2-carboxylate (22),
    ethyl 5-nitro-1H-indole-2-carboxylate (23),
    ethyl 3-(morpholinomethyl)-1H-indole-2-carboxylate (24),
    ethyl 3-(pyrrolidin-1-ylmethyl)-1H-indole-2-carboxylate (25),
    ethyl 5-amino-1H-indole-2-carboxylate (26),
    ethyl 5-ethynyl-1H-indole-2-carboxylate (27),
    ethyl 5-(prop-1-yn-1-yl)-1H-indole-2-carboxylate (28),
    ethyl 5-(but-1-yn-1-yl)-1H-indole-2-carboxylate (29),
    ethyl 5-(phenylethynyl)-1H-indole-2-carboxylate (30),
    ethyl 5-azido-1H-indole-2-carboxylate (31),
    ethyl 5-fluoro-1H-pyrrole-2-carboxylate (32),
    ethyl 5-chloro-1H-pyrrole-2-carboxylate (33),
    ethyl 5-bromo-1H-pyrrole-2-carboxylate (34),
    ethyl 5-iodo-1H-pyrrole-2-carboxylate (35),
    ethyl 5-nitro-1H-pyrrole-2-carboxylate (36).


In another embodiment of the present invention N-aminated substituted 2-carboxylate as obtained in step (a) is either N-aminated pyrrole substituted 2-carboxylate or N-aminated indole substituted 2-carboxylate.
In another embodiment of the present invention yield of triazine compounds of Formula II is in the range of 75 to 85%.



BRIEF DESCRIPTION OF ACCOMPANYING DRAWINGS
FIG. 1 depicts ORTEP diagram of the compound 38.
FIG. 2 depicts 1H NMR (CD3OD, 200 MHz) spectrum of 5,7-dimethylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one.
FIG. 3 depicts 1H NMR (CD3OD, 500 MHz) spectrum of pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one.
FIG. 4 depicts 1H NMR (DMSO-d6, 500 MHz) spectrum of 7-methoxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one.
FIG. 5 depicts 1H NMR (CD3OD, 400 MHz) spectrum of 7,8-dimethoxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one.
FIG. 6 depicts 1H NMR (DMSO-d6, 400 MHz) spectrum of 6-nitropyrrolo[2,1-f][1,2,4]triazin-4(3H)-one.
FIG. 7 depicts 1H NMR (CD3OD, 400 MHz) spectrum of [1,2,4]triazino[1,6-a]indol-4(3H)-one.



DETAILED DESCRIPTION OF THE INVENTION
The instant invention discloses triazine compounds and a short method to synthesize triazines nucleus, wherein the method comprises amination followed by Leuckart reaction conditions of pyrrole/indole-2-carboxylates of Formula I to obtain corresponding [1,2,4]triazine compounds of Formula II.
The instant invention thus provides short and efficient route for synthesis of various fused nitrogen ring system derivatives selected from a number of pyrrole and indole triazines. The synthesis of pyrrole triazinones and indole triazinones according to the invention has been accomplished in the instant invention using Leuckart reaction conditions.
The invention provides one pot method for synthesis of pyrrole/indole[1,2,4]triazine compounds of Formula II comprising steps of;

    
    
        (a) subjecting pyrrole/indole-2-carboxylate compounds of Formula I to amination in presence of chloramine to obtain desired N-aminated pyrrole/indole-2-carboxylate in high yields;
        (b) adding the N-aminated pyrrole/indole-2-carboxylate compound obtained from step (a) to formamide and ammonium acetate under Leuckart conditions to obtain pyrrole/indole[1,2,4]triazine compounds of Formula II.
    
    


N-Amination of various commercially available pyrrole-2-carboxylates and indole-2-carboxylates of Formula I is carried out using mono chloramine. N-amino pyrrole-2-carboxylate and N-amino-indole-2-carboxylates thus obtained were heated overnight at 140° C. under nitrogen atmosphere in formamide and ammonium acetate to give various pyrrole and indole triazine compounds of Formula II. The instant invention is schematically represented below in scheme 1.




wherein, R1, R2 and R3, are independently selected from the group consisting of hydrogen, (C1-C6) alkyl, —NO2, I, Cl, Br, F or —CH2—R7, where R7 is 5 or 6 membered saturated heterocyclic ring, comprising at least one heteroatom selected from the group consisting of N, O, S which is directly attached to carbon atom of —CH2 or

R1 and R2 together form substituted or unsubstituted aromatic ring as follow;





wherein R4, R5 and R6 is individually selected from the group consisting of hydrogen, (C1-C6) alkyl, —NH2, halogen, —OH, —CN, —NO2, aryl, alkylaryl, (C1-C8) alkoxy, aryloxy, arylalkoxy, N3, R—C≡C—, where R is hydrogen, (C1-C6)alkyl, aryl, alkylaryl.

The proposed mechanism for cyclization using Leuckart condition according to the invention is shown below in scheme 2:




According to preferred aspect, N-aminated ethyl 3,5-dimethyl-1H-pyrrole-2-carboxylate (6) is prepared by adding aqueous sodium hypochlorite at room temperature to a vigorously stirred mixture of ethyl 3,5-dimethyl-1H-pyrrole-2-carboxylate in Methyl tertiary-butyl ether (MTBE), ammonium chloride, methyltrioctylammonium chloride (Aliquat-336), aqueous NaOH and aqueous NH4OH. The resulting reaction mixture was stirred at room temperature for an additional 2-4 h at the end of which, the complete disappearance of starting material and formation of product is observed by capillary GC and HPLC. The upper product-rich organic layer was separated from the spent aqueous layer and washed with aqueous Na2S2O3. The organic layer is then dried over anhydrous Na2SO4 and evaporated in vacuo to produce N-aminated ethyl 3,5-dimethyl-1H-pyrrole-2-carboxylate (6). The N-amination of indole-2-carboxylate, pyrrole-2-carboxylate and their derivatives according to the invention has been achieved using chloramine, which is generated in the aqueous layer through oxidation of ammonia by NaOCl. At the same time, the substrate is deprotonated in the organic phase methyl tertiary-butyl ether (MTBE) with the addition of a small amount of methyltrioctylammonium chloride (Aliquat-336), which promptly reacts with the small portion of chloramines present in the organic layer, affording the desired N—NH2 derivative in high yields.
In another preferred aspect, the solution of N-aminated ethyl 3,5-dimethyl-1H-pyrrole-2-carboxylate (6) in formamide is added to NH4OAc under stirring. The resulting mixture is stirred for 12-14 h at reflux temperature. The reaction mixture is poured into cold water and further diluted with ethyl acetate. The layers are separated and the aqueous layer is repeatedly extracted with ethyl acetate and the combined organic layers are dried over Na2SO4, filtered, and concentrated. The solvents are removed under reduced pressure to give the crude product mixture as colorless solid. Silica gel column chromatography of the crude product using petroleum ether/EtOAc (3:1) as eluent gave (38) as a colorless crystalline solid.
The 1H NMR spectrum of 1 clearly indicated broad singlet for —NH2 at δ 4.68. Derivatives of N-amino pyrrole-2-carboxylate and N-amino-indole-2-carboxylates were heated overnight at 140° C. under nitrogen atmosphere in formamide and ammonium acetate to give cyclized pyrrole and indoletriazines.
In the present invention, various pyrroletriazinones and indoletriazinones have been accomplished using Leuckart reaction conditions from N-aminated precursors of pyrrole-2-carboxylate and N-amino-indole-2-carboxylates as depicted in table 1.







TABLE 1







One-pot synthesis of [1,2,4]triazino[1,6-a]indol-4(3H)-one and


[1,2,4]riazino[1,6-a]pyrrole-4(3H)-one compounds










Entry





No.
N-Amination precursors
Products
Yields













1.








83%


 


2.








84%


 


3.








78%


 


4.








81%


 


5.








85%


 


6.








73%


 


7.








67%


 


8.








—


 


9.








—


 


10.   








—


 


11.








—


 


12.








—


 


13.








—


 


14.








—


 


15.








—


 


16.








—


 


17.








—









The compounds of Formula II were synthesized according to invention encompasses triazine compounds as depicted in Table 2.







TABLE 2







IUPAC names of the compounds synthesized










Com-




pound



S. No.
No.
I.U.P.A.C Names





i.
37
pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


ii.
38
5,7-dimethylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


iii.
39
6-nitropyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


iv.
40
7-methylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


v.
04
[1,2,4]triazino[1,6-a]indol-4(3H)-one


vi.
41
7-methoxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one


vii.
42
7,8-dimethoxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one


viii.
43
7-(benzyloxy)-[1,2,4]triazino[1,6-a]indol-4(3H)-one


ix.
44
4-oxo-3,4-dihydro-[1,2,4]triazino[1,6-a]indole-7-




carbonitrile


x.
45
7-fluoro-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xi.
46
7-chloro-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xii.
47
7-bromo-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xiii.
48
7-iodo-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xiv.
49
7-hydroxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xv.
50
6-fluoro-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xvi.
51
6-chloro-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xvii.
52
6-bromo-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xviii.
53
6-iodo-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xix.
54
6-hydroxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xx.
55
7-nitro-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xxi.
56
5-(morpholinomethyl)-[1,2,4]triazino[1,6-a]indol-




4(3H)-one


xxii.
57
5-(pyrrolidin-1-ylmethyl)-[1,2,4]triazino[1,6-a]indol-




4(3H)-one


xxiii.
58
7-amino-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xxiv.
59
7-ethynyl-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xxv.
60
7-(but-1-yn-1-yl)-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xxvi.
61
7-(pent-1-yn-1-yl)-[1,2,4]triazino[1,6-a]indol-4(3H)-




one


xxvii.
62
7-(phenylethynyl)-[1,2,4]triazino[1,6-a]indol-4(3H)-




one


xxviii.
63
7-azido-[1,2,4]triazino[1,6-a]indol-4(3H)-one


xxix.
64
7-fluoropyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


xxx.
65
7-chloropyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


xxxi.
66
7-bromopyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


xxxii.
67
7-iodopyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


xxxiii.
68
7-nitropyrrolo[2,1-f][1,2,4]triazin-4(3H)-one









The N-aminated precursors as well as cyclized triazines are characterized by spectral data. The 1H NMR spectrum of compound 38 showed the presence of olefinic proton at δ 7.52 (s, 1H) and in 13C NMR spectrum of compound 38 showed the presence of amide carbonyl at 159.9 ppm. confirms the formation of [1,2,4]triazino[1,6-a]indol-4(3H)-one and [1,2,4]triazino[1,6-a]pyrrole-4(3H)-one. Further in order to confirm reaction product 38, recrystallisation was done by slow evaporation of the solution mixture of ethyl acetate and hexane to give the clear crystalline solid, which was analysed for single X-ray crystallography. The ORTEP diagram (FIG. 1) clearly established the formation of triazines.
The present invention encompasses novel triazine compounds of Formula II,




wherein, R1, R2, and R3, are independently selected from the group consisting of hydrogen, (C1-C6) alkyl, —NO2, I, Cl, Br, F, and —CH2—R7, where R7 is 5 or 6 membered saturated heterocyclic ring, comprising at least one heteroatom selected from the group consisting of N, O, and S Which is directly attached to carbon atom of —CH2; or

R1 and R2 together form substituted or unsubstituted aromatic ring as set forth below:





wherein R4, R5, and R6 are individually selected from the group consisting of hydrogen, (C1-C6) alkyl, —NH2, halogen, —OH, —CN, —NO2, aryl, alkylaryl, (C1-C8) alkoxy, aryloxy, arylalkoxy, N3, and R—C≡C—, where R is selected from the group consisting of hydrogen, (C1-C6)alkyl, aryl, and alkylaryl.

According to the invention, the novel triazine compounds of Formula H, are selected from the group consisting of:











Com-



pound



No.
I.U.P.A.C Names







38
5,7-dimethylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


04
[1,2,4]triazino[1,6-a]indol-4(3H)-one


41
7-methoxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one


42
7,8-dimethoxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one


43
7-(benzyloxy)-[1,2,4]triazino[1,6-a]indol-4(3H)-one


44
4-oxo-3,4-dihydro-[1,2,4]triazino[1,6-a]indole-7-carbonitrile


45
7-fluoro-[1,2,4]triazino[1,6-a]indol-4(3H)-one


46
7-chloro-[1,2,4]triazino[1,6-a]indol-4(3H)-one


47
7-bromo-[1,2,4]triazino[1,6-a]indol-4(3H)-one


48
7-iodo-[1,2,4]triazino[1,6-a]indol-4(3H)-one


49
7-hydroxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one


50
6-fluoro-[1,2,4]triazino[1,6-a]indol-4(3H)-one


51
6-chloro-[1,2,4]triazino[1,6-a]indol-4(3H)-one


52
6-bromo-[1,2,4]triazino[1,6-a]indol-4(3H)-one


53
6-iodo-[1,2,4]triazino[1,6-a]indol-4(3H)-one


54
6-hydroxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one


55
7-nitro-[1,2,4]triazino[1,6-a]indol-4(3H)-one


56
5-(morpholinomethyl)-[1,2,4]triazino[1,6-a]indol-4(3H)-one


57
5-(pyrrolidin-1-ylmethyl)-[1,2,4]triazino[1,6-a]indol-4(3H)-one


58
7-amino-[1,2,4]triazino[1,6-a]indol-4(3H)-one


59
7-ethynyl-[1,2,4]triazino[1,6-a]indol-4(3H)-one


60
7-(but-1-yn-1-yl)-[1,2,4]triazino[1,6-a]indol-4(3H)-one


61
7-(pent-1-yn-1-yl)-[1,2,4]triazino[1,6-a]indol-4(3H)-one


62
7-(phenylethynyl)-[1,2,4]triazino[1,6-a]indol-4(3H)-one


63
7-azido-[1,2,4]triazino[1,6-a]indol-4(3H)-one


64
7-fluoropyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


65
7-chloropyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


66
7-bromopyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


67
7-iodopyrrolo[2,1-f][1,2,4]triazin-4(3H)-one


68
7-nitropyrrolo[2,1-f][1,2,4]triazin-4(3H)-one









In another embodiment, the present invention provides a pharmaceutical composition comprising instant triazine compounds of Formula II or its pharmaceutically acceptable salts, along with pharmaceutically acceptable excipients or carriers, for the treatment of cancer in human. Further the composition may be formulated into preparations such as solid, semi-solid, liquid or gaseous forms, such as tablets, capsules, powders, granules, ointments, syrup, solutions, injections, gels and microspheres etc.
Generally, the quantity of active compound of Formula II ranges between 0.5% to 90% by weight of the composition. Normally, the effective amount of dosage of triazine compounds will be in the range of about 0.1 to about 100 mg/kg, more preferably about 1.0 mg to about 50 mg/kg of body weight/day.
The pharmaceutical compositions of the invention can be prepared by combining a compound of Formula II the invention with an appropriate pharmaceutically acceptable carrier, diluent or excipient. The excipients or carriers are selected from the group such as diluents, disintegrants, binders, lubricants, coatings layer, stabilizers, preservatives, glidants.
In another embodiment, the present invention relates to administering ‘an effective amount’ of the ‘composition of invention’ to the subject suffering from cancer. Typical routes of administering such pharmaceutical compositions include, oral, topical, transdermal, inhalation, parenteral, sublingual, buccal, rectal, vaginal, and intranasal.
The invention provides method of inhibiting tyrosine kinase comprises administering an effective amount of triazine compounds of Formula II or its pharmaceutical salt in association with one or more pharmaceutical carriers/excipients.
In another embodiment, the invention provides a method of treating or inhibiting growth of cancer cells in a subject comprising administrating triazine compounds of Formula II optionally comprising administering at least one additional active compound together with pharmaceutically acceptable excipients and/or vehicles,
Further invention provides use of triazine compounds of Formula II for the preparation of medicament useful for treating or inhibiting the growth of cancer cells in a subject. The subject disclosed in the invention is human.
EXAMPLES
Following are the examples given to further illustrate the invention and should not be construed to limit the scope of the present invention.
Example 1
General Experimental Procedure for N-Amination Reaction
Aqueous sodium hypochlorite (58.76 ml of ca. 9% solution) was added over a period of 20 min, at room temperature (25° C.), to a vigorously stirred mixture of (3,4,5,6-substituted-1-H-pyrrole/indole-2-carboxylic acid ethyl ester) (2 g, 8.9 mmol) in MTBE (24 ml), ammonium chloride (2.9 g, 53.2 mmol), methyltrioctylammonium chloride (Aliquat-336) (0.1 g), aqueous NaOH (25.6 ml of 28.4% solution) and aqueous NH4OH (8.28 ml of 28% solution). The resulting reaction mixture was stirred at room temperature for an additional 2-4 h at the end of which time the complete disappearance of starting material and formation of product was observed by capillary GC and HPLC. The upper product-rich organic layer was separated from the spent aqueous layer and washed with aqueous Na2S2O3 (40 ml). The organic layer was then dried over anhydrous Na2SO4 and evaporated in vacuo to produce 2.01 g of (1-amino-3,4,5,6-substituted-1-H-pyrrole/indole-2-carboxylic acid ethyl ester) (94% yield).
Example 2
General Experimental Procedure for Cyclization Reaction
To a stirring solution of (1-amino-3,4,5,6-substituted-1-H-pyrrole/indole-2-carboxylic acid ethyl ester) in formamide (5 ml) was added NH4OAc. The resulting mixture was heated overnight at 140° C. under nitrogen atmosphere. The mixture was poured into cold water and further diluted with ethyl acetate. The layers were separated and the aqueous layer was extracted with ethyl acetate (2×20 mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated. The solvents were removed under reduced pressure to give the crude product mixture as colorless solid. Silica gel column chromatography of the crude product using petroleum ether/EtOAc (3:1) as eluent gave (Pyrrolo/Indole[1,2,4]triazin-4(3H)-one) (83% yield) as a colorless crystalline solid.
Using the above procedure, the following cyclized triazines compounds have been prepared.
Example 3
5,7-dimethylpyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (38)
















Mol.

Equiv-
Den-
Weight/


Name of Compound
Wt
mmoles
alent
sity
volume





















ethyl 1-amino-3,5-
163.18
1.23
1

200
mg


dimethyl-1H-pyrrole-








2-carboxylate








NH4OAc
77.08
1.845
1.5

142.21
mg


Time & Temp
140° C.








& 12 h









Example 4
pyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (37)
















Mol.

Equiv-
Den-
Weight/


Name of Compound
Wt
mmoles
alent
sity
volume





















ethyl 1-amino-1H-
135.12
1.48
1

200
mg


pyrrole-2-carboxylate








NH4OAc
77.08
2.22
1.5

171.12
mg


Time & Temp
140° C.








& 12 h









Example 5
7-methoxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one (41)
















Mol.

Equiv-
Den-
Weight/


Name of Compound
Wt
mmoles
alent
sity
volume





















ethyl 1-amino-5-
215.07
0.93
1

200
mg


methoxy-1H-indole-








2-carboxylate








NH4OAc
77.08
1.4
1.5

107.53
mg


Time & Temp
140° C.








& 12 h









Example 6
7,8-dimethoxy-[1,2,4]triazino[1,6-a]indol-4(3H)-one (42)
















Mol.

equiv-
den-
Weight/


Name of Comp.
Wt
mmoles
alent
sity
volume





















ethyl 1-amino-5,6-
245.23
0.82
1

200
mg


dimethoxy-1H-








indole-2-carboxylate








NH4OAc
77.08
1.23
1.5

94.80
mg


Time & Temp
140° C.








& 12 h









Example 7
6-nitropyrrolo[2,1-f][1,2,4]triazin-4(3H)-one (39)
















Mol.

Equiv-
Den-
Weight/


Name of Compound
Wt
mmoles
alent
sity
volume





















ethyl 1-amino-4-nitro-
180.12
1.11
1

200
mg


1H-pyrrole-2-








carboxylate








NH4OAc
77.08
1.67
1.5

128.34
mg


Time & Temp
140° C.








& 12 h









Example 8
[1,2,4]triazino[1,6-a]indol-4(3H)-one (04)
















Mol.

Equiv-
Den-
Weight/


Name of Compound
Wt
mmoles
alent
sity
volume





















ethyl 1-amino-1H-
185.18
1.08
1

200
mg


indole-2-carboxylate








NH4OAc
77.08
1.62
1.5

124.87
mg


Time & Temp
140° C.








& 12 h









ADVANTAGES OF INVENTION
The instant method is short and efficient for synthesis of various fused nitrogen ring system derivatives also the method avoids cumbersome intermediate steps and expensive solvents. Therefore, the instant invention is cost effective and industrially viable.

## Claims

1. A triazine compound of Formula II,



wherein, R1 is selected from the group consisting of hydrogen, —NO2, Br, F, and —CH2—R7, where R7 is 5 or 6 membered saturated heterocyclic ring, comprising at least one heteroatom selected from the group consisting of N, O, and S which is directly attached to carbon atom of —CH2; and
wherein R2 is selected from the group consisting of —NO2, I, Cl, F, and —CH2—R7, wherein R7 is a 5 or 6 membered saturated heterocyclic ring, comprising at least one heteroatom selected from the group consisting of N, O, and S, which is directly attached to carbon atom of —CH2; and
wherein R3 is selected from the group consisting of hydrogen, —NO2, I, F, and —CH2—R7, wherein R7 is a 5 or 6 membered saturated heterocyclic ring, comprising at least one heteroatom selected from the group consisting of N, O, and S, which is directly attached to carbon atom of —CH2; or
R1 and R2 together form substituted or unsubstituted aromatic ring as set forth below:




wherein R4, R5, and R6 are individually selected from the group consisting of hydrogen, (C1-C6) alkyl, —NH2, halogen, —OH, —CN, —NO2, aryl, alkylaryl, (C1-C8) alkoxy, aryloxy, arylalkoxy, N3, and R—C≡C—, where R is selected from the group consisting of hydrogen, (C1-C6)alkyl, aryl, and alkylaryl.

2. The triazine compound as claimed in claim 1, wherein the structural formula of the representative compound is selected from the group consisting of:

3. A process for the preparation of triazine compound of Formula II as claimed in claim 1, said process comprising the steps of:
(a) stirring compound of Formula I with sodium hypochlorite, Methyl tertiary-butyl ether (MTBE), methyltrioctylammonium chloride (aliquat-336), aqueous NaOH, ammonium chloride and aqueous NH4OH at a temperature ranging between 25° C. to 35° C. for a period ranging between 2-4 hrs to obtain N-aminated substituted 2-carboxylate;





wherein, R1 is selected from the group consisting of hydrogen, —NO2, Br, F, and —CH2—R7, where R7 is 5 or 6 membered saturated heterocyclic ring, comprising at least one heteroatom selected from the group consisting of N, O, and S which is directly attached to carbon atom of —CH2; and
wherein R2 is selected from the group consisting of —NO2, I, Cl, F, and —CH2—R7, wherein R7 is a 5 or 6 membered saturated heterocyclic ring, comprising at least one heteroatom selected from the group consisting of N, O, and S, which is directly attached to carbon atom of —CH2; and
wherein R3 is selected from the group consisting of hydrogen, —NO2, I, F, and —CH2—R7 wherein R7 is a 5 or 6 membered saturated heterocyclic ring, comprising at least one heteroatom selected from the group consisting of N, O, and S, which is directly attached to carbon atom of —CH2; or
R1 and R2 together form substituted or unsubstituted aromatic ring as set forth below:






wherein R4, R5, and R6 are individually selected from the group consisting of hydrogen, (C1-C6) alkyl, —NH2, halogen, —OH, —CN, —NO2, aryl, alkylaryl, (C1-C8) alkoxy, aryloxy, arylalkoxy, N3, and R—C≡C, where R is selected from the group consisting of hydrogen, (C1-C6)alkyl, aryl, and alkylaryl

(b) heating the N-aminated substituted 2-carboxylate compounds as obtained in step (a) with formamide and ammonium acetate at 130° C. to 140° C. for a period ranging between 10 to 12 hr under nitrogen atmosphere to obtain triazine compound of Formula II.

4. The process as claimed in claim 3, wherein the compound of Formula I is selected from the group consisting of:
ethyl 1H-pyrrole-2-carboxylate (5),
ethyl 3,5-dimethyl-1H-pyrrole-2-carboxylate (6),
ethyl 4-nitro-1H-pyrrole-2-carboxylate (7),
ethyl 5-methyl-1H-pyrrole-2-carboxylate (8),
ethyl 1H-indole-2-carboxylate (1),
ethyl 5-methoxy-1H-indole-2-carboxylate (9),
ethyl 5,6-dimethoxy-1H-indole-2-carboxylate (10),
ethyl 5-(benzyloxy)-1H-indole-2-carboxylate (11),
ethyl 5-cyano-1H-indole-2-carboxylate (12),
ethyl 5-fluoro-1H-indole-2-carboxylate (13),
ethyl 5-chloro-1H-indole-2-carboxylate (14),
ethyl 5-bromo-1H-indole-2-carboxylate (15),
ethyl 5-iodo-1H-indole-2-carboxylate (16),
ethyl 5-hydroxy-1H-indole-2-carboxylate (17),
ethyl 4-fluoro-1H-indole-2-carboxylate (18),
ethyl 4-chloro-1H-indole-2-carboxylate (19),
ethyl 4-bromo-1H-indole-2-carboxylate (20),
ethyl 4-iodo-1H-indole-2-carboxylate (21),
ethyl 4-hydroxy-1H-indole-2-carboxylate (22),
ethyl 5-nitro-1H-indole-2-carboxylate (23),
ethyl 3-(morpholinomethyl)-1H-indole-2-carboxylate, (24),
ethyl 3-(pyrrolidin-1-ylmethyl)-1H-indole-2-carboxylate (25),
ethyl 5-amino-1H-indole-2-carboxylate (26),
ethyl 5-ethynyl-1H-indole-2-carboxylate (27),
ethyl 5-(prop-1-yn-1-yl)-1H-indole-2-carboxylate (28),
ethyl 5-(but-1-yn-1-yl)-1H-indole-2-carboxylate (29),
ethyl 5-(phenylethynyl)-1H-indole-2-carboxylate (30),
ethyl 5-azido-1H-indole-2-carboxylate (31),
ethyl 5-fluoro-1H-pyrrole-2-carboxylate (32),
ethyl 5-chloro-1H-pyrrole-2-carboxylate (33),
ethyl 5-bromo-1H-pyrrole-2-carboxylate (34),
ethyl 5-iodo-1H-pyrrole-2-carboxylate (35), and
ethyl 5-nitro-1H-pyrrole-2-carboxylate (36).

5. The process as claimed in claim 3, wherein N-aminated substituted 2-carboxylate as obtained in step (a) is either N-aminated pyrrole substituted 2-carboxylate or N-aminated indole substituted 2-carboxylate.

6. The process as claimed in claim 3, wherein yield of triazine compound of Formula II is in the range of 75 to 85%.